0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Panacos Pharmaceuticals
Its shares trade under the ticker PANC. It has been listed since 11 June 1998. In the fiscal year to 31 December 2007, it reported revenue of $180,000 and a net loss of $37.5m. At that date it held total assets of $55.7m and shareholders' equity of $28.9m.
Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. The company is headquartered in Watertown, Massachusetts. The firm's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The firm has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jun 1998
- Employees
- 41
Leadership
Pay as last reported
- Jeremy Hayward-SurryChairman of the Board, since 1997
- Dr. Alan DuntonPresident, Chief Executive Officer, Director, since 2007$1.5m
- Mr. David MartinSenior Vice President - Drug Development
- Mr. Robert PelletierVice President - Finance, Principal Accounting Officer$355,944
- Dr. Tom LateganVice President - Regulatory Affairs
- Dr. Laurent FischerDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Competitive Product Portfolio: Panacos Pharmaceuticals Inc has a diverse range of products that cater to different therapeutic areas, providing a competitive advantage in the pharmaceutical industry. This strong product portfolio helps to minimize risks associated with limited product offerings.
- Robust Research and Development (R&D): The company's strong focus on R&D enables the development of innovative drugs and breakthrough technologies, ensuring a continuous pipeline of new products. This emphasis on R&D enhances Panacos Pharmaceuticals' ability to stay ahead of competitors and capture market opportunities.
- Strong Intellectual Property (IP) Portfolio: The company possesses a significant number of patents and trademarks, safeguarding its inventions and preventing competitors from infringing on its discoveries. This helps protect market share and maintain a sustainable competitive advantage.
Weaknesses
- Limited Market Reach: Panacos Pharmaceuticals currently operates in a limited number of geographic regions, which restricts its access to potential customers and market opportunities. Expanding into new markets can be challenging and resource-intensive.
- Dependency on Third-Party Relationships: The company heavily relies on third-party contract manufacturers, suppliers, and distribution companies for the production, supply chain, and distribution of its products. This dependency introduces risks such as quality control, availability, and pricing fluctuations.
- Lack of Brand Recognition: Compared to larger pharmaceutical companies, Panacos Pharmaceuticals has a relatively lower brand recognition in the industry. This may hinder customer trust and lead to difficulties in positioning and promoting its products effectively.
Opportunities
- Emerging Markets: Expanding into emerging markets such as Asia and Latin America presents significant growth opportunities for Panacos Pharmaceuticals. These regions have a rising demand for healthcare products and offer a large customer base.
- Strategic Collaborations: Partnering with established pharmaceutical companies or research institutions can provide access to additional resources, expertise, and a wider customer reach. Collaborations can accelerate product development, reduce costs, and enhance market penetration.
- Technological Advancements: Keeping up with advances in technology, such as digital health solutions and personalized medicine, can enable Panacos Pharmaceuticals to develop innovative products and better meet the evolving needs of patients and healthcare providers.
Threats
- Intense Competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Panacos Pharmaceuticals faces the risk of competitors launching similar products or implementing aggressive pricing strategies that may impact its market position and profitability.
- Stringent Regulations: Compliance with strict regulatory requirements, including clinical trials, approvals, and safety regulations, can add complexity and delays to the development and commercialization of pharmaceutical products.
- Economic Factors: Fluctuations in the global economy, currency exchange rates, and healthcare policies can affect the affordability and demand for pharmaceutical products. Panacos Pharmaceuticals needs to monitor and adapt to economic trends to mitigate potential risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.